Cell therapy translational research platforms are limited. Xsphera Biosciences is excited to introduce XspheraCT, a purpose built translational research program that leverages the microfluidics, human tissue platform for cell therapy developers. Using a diversity of in-house tools and fresh human tissue, XspheraCT allows developers of cancer cell therapy to better elucidate lead optimization, candidate profiling and patient stratification. To demonstrate the power of XspheraCT, our team has created a white paper that describes the necessity for more advanced approaches in cell therapy translational research. We also demonstrate our proof of concept and published, peer-reviewed evidences in human tumor samples. Click the link below to access the white paper, peruse our website offerings and reach out to the team at sales@xspherabio.com. https://lnkd.in/gbHCAdnW We look forward to helping you develop your cell therapy program! #celltherapy #oncology #cancer #PDOTS #TME #tumormicroenvironment #immunooncology #solidtumor
AIM Biotech is pleased to see its #idenTx microfluidic devices being used for cell therapy assays. We’re here to help our partners succeed with AIM-enabled assays, with versatile, easy-to-operate devices that fit directly into existing automated workflows.
Xsphera Biosciences Inc and Stephen Remondi congrats on the release of XspheraCT and this exciting program! Desperately needed for pre-clinical development of cell therapies, which demand more advanced biotools.
Congratulations on marking this new chapter in your journey!
Congratulations Steve - such exciting and important work!
Sounds incredible Steve - Congratulations!
CEO & Founder at Xsphera Biosciences Inc
4moWe are very excited to be officially launching our cell therapy focused platform!